ArticleDrugs in context2022

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors.

Federico Sottotetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.